main-logo

ICD-10 Code C85.18 | Unspecified B-cell lymphoma, lymph nodes of multiple sites Symptoms, Diagnosis, Billing

Unspecified B-cell lymphoma, lymph nodes of multiple sites is a type of non-Hodgkin lymphoma characterized by the proliferation of B-lymphocytes in lymph nodes across multiple anatomical sites. This condition is clinically significant due to its potential for aggressive behavior and varied treatment responses. Accurate coding with ICD-10 Code C85.18 is essential for proper diagnosis, documentation, medical billing, and public health reporting, ensuring that healthcare providers can effectively track and manage patient outcomes.

What is ICD-10 Code C85.18 for Unspecified B-cell lymphoma, lymph nodes of multiple sites?

ICD-10 Code C85.18 represents Unspecified B-cell lymphoma, lymph nodes of multiple sites, indicating a diagnosis of lymphoma affecting multiple lymph node regions without specific subtype classification. This code is used when the precise type of B-cell lymphoma is not determined, and it is crucial for clinical documentation and billing purposes, particularly in oncology settings.

ICD-10 Code C85.18 – Clinical Definition and Explanation of Unspecified B-cell lymphoma, lymph nodes of multiple sites

Unspecified B-cell lymphoma, lymph nodes of multiple sites, is a hematological malignancy that arises from B-lymphocytes, leading to lymphadenopathy and potential systemic symptoms. The etiology may involve genetic mutations, environmental factors, or immune dysregulation. Prompt diagnosis and treatment are critical due to the risk of disease progression.

Key Clinical Features:

  • Lymphadenopathy in multiple regions, often asymptomatic initially.
  • Possible systemic symptoms including fever, night sweats, and weight loss.
  • Diagnosis typically confirmed through biopsy and histological examination.
  • Potential for transformation into more aggressive forms of lymphoma.

ICD-10 Code C85.18 for Unspecified B-cell lymphoma, lymph nodes of multiple sites – SOAP Notes & Clinical Use

ICD-10 Code C85.18 is utilized in SOAP notes to document the presence of unspecified B-cell lymphoma affecting multiple lymph nodes. It plays a vital role in capturing patient symptoms, assessments, and treatment plans, ensuring comprehensive documentation in both acute and chronic care settings.

What Does ICD-10 Code C85.18 for Unspecified B-cell lymphoma, lymph nodes of multiple sites Mean in SOAP Notes?

In SOAP notes, ICD-10 Code C85.18 connects subjective patient reports and objective clinical findings to a formal diagnosis of unspecified B-cell lymphoma. This code is essential for maintaining continuity of care, supporting accurate billing, and meeting EHR documentation standards.

Treatment Options for ICD-10 Code C85.18 – Unspecified B-cell lymphoma, lymph nodes of multiple sites

The management of unspecified B-cell lymphoma, lymph nodes of multiple sites, often necessitates hospitalization for comprehensive evaluation and treatment. Therapeutic approaches may include chemotherapy, targeted therapy, or immunotherapy.

Antibiotic Therapy:

  • Not applicable as this condition is not infectious.

Supportive Care:

  • Symptom management including pain control and nutritional support.
  • Monitoring for complications such as infections or tumor lysis syndrome.
  • Psychosocial support for patients and families.

Infection Control:

  • Standard precautions to prevent infections in immunocompromised patients.
  • Education on hygiene and avoiding exposure to infectious agents.

How to Document Symptoms of Unspecified B-cell lymphoma, lymph nodes of multiple sites (ICD-10 C85.18) in SOAP Notes

Subjective:

  • Patient reports persistent swelling in multiple lymph node regions.
  • Complaints of unexplained weight loss over the past few months.
  • Experiencing night sweats and occasional fevers.
  • No significant past medical history reported.

Objective:

  • Physical examination reveals enlarged lymph nodes in cervical and axillary regions.
  • Vital signs: Temperature 100.4°F, pulse 85 bpm, blood pressure 120/80 mmHg.
  • Laboratory tests show elevated lactate dehydrogenase (LDH) levels.
  • Imaging studies indicate lymphadenopathy in multiple sites.
card-topcard-bottom

Secure, compliant, and built for trust

HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.

Learn more
hipaa-icon

SOAP Note Guidelines for Diagnosing Unspecified B-cell lymphoma, lymph nodes of multiple sites (ICD-10 Code C85.18)

Assessment:

  • Diagnosis: Unspecified B-cell lymphoma, lymph nodes of multiple sites, moderate severity.
  • ICD-10 Code: C85.18.
  • Contributing factors: Possible genetic predisposition and environmental exposures.
  • Patient exhibits symptoms consistent with lymphoma.

Plan:

  • Initiate chemotherapy regimen based on oncologist's recommendations.
  • Schedule follow-up appointments for monitoring treatment response.
  • Provide education on potential side effects and supportive care measures.
  • Consider referral to a palliative care specialist for symptom management.

Treatment & Plan Section for ICD-10 Code C85.18 – Unspecified B-cell lymphoma, lymph nodes of multiple sites

  • First-line pharmacologic treatments may include CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) chemotherapy.
  • Non-pharmacologic strategies include nutritional support and psychosocial counseling.
  • Monitoring practices should involve regular imaging and laboratory tests to assess treatment efficacy.
  • Follow-up appointments should be scheduled every 1-3 months to evaluate patient progress.

Using ICD-10 Code C85.18 for Unspecified B-cell lymphoma, lymph nodes of multiple sites in Billing & SOAP Note Compliance

  • Select accurate subcodes based on clinical severity or complications.
  • Document symptoms clearly under Subjective (S) and Objective (O) in SOAP notes.
  • Ensure treatment plans align with clinical guidelines to support justified billing.
  • Only list CPT codes that are commonly billed with ICD-10 Code C85.18 based on standard medical coding practices.

ICD-10 Code C85.18 in Medical Billing and Insurance for Unspecified B-cell lymphoma, lymph nodes of multiple sites

ICD-10 Code C85.18 is critical in medical billing, particularly in hospital, ER, or infectious disease care settings.

Billing Notes:

  • Ensure thorough documentation of patient history and clinical findings to support the ICD-10 claim.
  • Use this code in conjunction with appropriate CPT codes for treatment and diagnostic procedures.
  • Maintain accurate records of all services rendered to facilitate reimbursement.
  • Review payer-specific guidelines for coding and billing requirements.

Common CPT Pairings:

CPT CodeDescription
96413Chemotherapy administration, intravenous, push technique, single or initial substance.
85025Complete blood count (CBC) with automated differential white blood cell count.
77014Radiologic examination, lymphatic system, including lymphangiography.
99223Initial hospital care, typically 70 minutes or more of total time on the date of the encounter.

Frequently Asked Questions

Common Questions About Using ICD-10 Code C85.18 for Unspecified B-cell lymphoma, lymph nodes of multiple sites

What are the common symptoms of unspecified B-cell lymphoma?

Common symptoms include swollen lymph nodes, unexplained weight loss, fever, and night sweats. Patients may also experience fatigue and itching. These symptoms can vary based on the extent of the disease.

How is unspecified B-cell lymphoma diagnosed?

Diagnosis typically involves a combination of physical examination, imaging studies, and biopsy of affected lymph nodes. Histological analysis is crucial for confirming the diagnosis and determining the specific type of lymphoma.

What treatment options are available for unspecified B-cell lymphoma?

Treatment options may include chemotherapy, targeted therapy, and immunotherapy. The choice of treatment depends on the stage of the disease, patient health, and specific lymphoma characteristics.

Is hospitalization required for patients with unspecified B-cell lymphoma?

Hospitalization may be necessary for initial treatment, especially for chemotherapy administration or management of complications. Continuous monitoring is essential to address any adverse effects or disease progression.

diamond-bg
diamond-bg

Get started with your 20 free notes

Sign up for free
main-logo

AI-aided Sudsy Shorthand for ink-free practices

support@soapsuds.io
hipaa-logo

Clinical Notes

SOAP notes

DAP notes

AI medical notes

© Copyright SOAPsuds 2025. All rights reserved